Results 101 to 110 of about 13,707,731 (353)

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Life after patch testing: Allergic contact dermatitis caused by propylene glycol in Vivelle transdermal estradiol patch

open access: yesJAAD Case Reports, 2021
Gurbani Kaur, AB   +2 more
doaj  

Patch Testing In Soldiers : An Evaluation

open access: yesIndian Journal of Dermatology, 2004
Our study concerns contact sensitization in soldiers, the frequency of which is poorly documented. During a six-year period, 128 patients of age range 17-50 years were patch tested with the Indian standard battery of 30 allergens.
Walia N. S, Jaiswal A. K
doaj  

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

open access: yesMolecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach   +8 more
wiley   +1 more source

Positive nickel patch tests do not intensify positive reactions to adjacent patch tests with dichromate [PDF]

open access: bronze, 2000
Jochen Brasch   +7 more
openalex   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner   +6 more
wiley   +1 more source

Patch Testing in Patients With Alopecia Areata: A Case-series Study. [PDF]

open access: yesDermatol Pract Concept, 2022
Kyrmanidou E   +5 more
europepmc   +1 more source

Results of patch testing with lavender oil in Japan [PDF]

open access: bronze, 2000
Mariko Sugiura   +4 more
openalex   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

open access: yesMolecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy